Structure Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and announced a $118 price target.
Portfolio Pulse from Benzinga Newsdesk
Structure Therapeutics shares rose after Morgan Stanley initiated coverage with an Overweight rating and a $118 price target.
September 23, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley's initiation of coverage with an Overweight rating and a $118 price target has positively impacted Structure Therapeutics' stock.
The Overweight rating and high price target from a reputable firm like Morgan Stanley is likely to increase investor confidence and demand for GPCR shares, leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100